垂体催乳素瘤的病因及发病机制的实验研究

应用在同一只雄性ＳＤ大鼠中,保留原位垂体并在肾囊内植入一异体垂体,同时背部埋植装有１７－β－雌二醇（１７－β－ｅｓｔｒａｄｉｏｌ,Ｅ２）的药泵,经Ｅ２在体作用６０￣１２０天后,其原位垂体和异体移植入肾囊的垂体同时形成２垂体催乳素（ｐｒｏｌａｃｔｉｎ,ＰＲＬ）瘤的动物模型,研究ＰＲＬ瘤的发病机制。结果表明,Ｅ２长期作用可诱发原位垂体和远离下丘脑的移植垂体同时形成ＰＲＬ瘤,并伴高ＰＲＬ血症和ＰＲＬ基因     

17—β—雌二醇诱发SD大鼠催乳素瘤形成过程中催乳素基因的表达

给SD大鼠皮下埋植内含17－β－雌二醇硅橡胶管30、60、120天后,发现大鼠垂体重量随给药时间延长呈持续性增加;用放射免疫法测定血浆催乳素（prolactin,PRL)含量,亦明显依次升高;用Northern印迹杂交方法检测垂体细胞中PRL基因,发现PRLmRNA含量也依次有显著增加,但其增加却远低于血浆PRL含量的增加,提示17－β－雌二醇除了促进PRL基因的转录外,还可能增加PRL mRNA的翻译效率。     

GRP和VIP对E2诱致的垂体催乳素（PRL）瘤细胞PRL基因转录的影响

实验应用雄性ＳＤ大鼠,皮下埋植内置１０ｍｇ雌二醇硅胶管３个月致体催乳素瘤后,取ＰＲＬ瘤细胞进行外原代培养,并应用原位杂交方法,研究不同剂量的胃泌素释放肽（ｇａｓｔｒｉｎ－ｒｅｌｅａｉｎｇｐｅｐｔｉｄｅ,ＧＲＰ）和血活性肠肽（ｖａｓｏａｃｔｉｖｅｉｎｔｅｓｔｉｎａｌｐｏｌｙｐｅｐｔｉｄｅ,ＶＩＰ）以及Ｅ２对 离体培养的垂体ＰＲＬ瘤细胞ＰＲＬ基因转录的,下,ＧＲＰ,ＶＩＰ分别与ＰＲＬ瘤细胞孵育２４ｈ后     

褪黑素通过减弱催乳素基因增强子的突变抑制大鼠垂体催乳素瘤的增生

本工作旨在探讨褪黑素(melatonin,MLT)抑制17-β-雌二醇(17-β-estradiol,E2)诱发的Sprague-Dawley大鼠垂体催乳素(prolactin,PRL)瘤增生的分子机制。结果表明,每只大鼠每日定时皮下注射一定剂量的MLT(0.25、0.50mg)能显著抑制E2诱发的大鼠垂体PRL瘤的增生;偏低(0.05mg)或过高剂量(1.00、2.00mg)的MLT也抑制PRL瘤的增生,但无统计学意义。采用PCR和DNA直接测序显示,与正常垂体对照组比较,PRL瘤中PRL基因增强子出现五处突变,-1885bp位点由C突变为G,-1857~-1855由ACA替换为G,-1792~-1791插入G,-1383~-1382插入GGTGTGTG片段,-1265~-1250缺失GTGTGTGTGTGTGTGT片段。0.25mg/dMLT处理组,PRL瘤中的PRL基因增强子上述个别突变部位仍然存在(-1885由C突变为G),突变消失(-1792~-1791无插入G),大部分表现为突变减弱(-1856~-1855缺失AC,-1385~-1384缺失TG,-1250~-1253缺失GTGT)。采用荧光素酶报告基因检测PRL基因增强子活性显示,正常垂体、PRL瘤和0.25mg/dMLT处理的PRL瘤三组中,PRL基因增强子的活性分别为(13448.17±3012.74)、(161831.67±60996.01)和(10212.17±2634.71)OD单位。PRL瘤组增强子活性较正常垂体升高11倍(P<0.001),MLT处理组增强子活性较PRL瘤组降低93.69%(P<0.001)。上述三组PRL基因增强子空间结构的分析表明,PRL基因增强子DNA的曲折程度为PRL瘤组>MLT处理组>正常垂体。以上结果证实,MLT抑制大鼠垂体PRL瘤增生的重要分子机制之一可能是减弱PRL基因增强子的突变,也提示MLT可减弱PRL基因增强子的突变,从而下调PRL基因的高表达,可能与降低DNA的曲折程度有关。     

营养缺乏与脂质过氧化的关系

人体必需的营养素如含硫氨基酸、维生素A、B_2、C、E、辅酶Q等以及微量元素铜、锌、锰、硒等均有抗氧化作用;果糖能加重脂质过氧化作用,葡萄糖或淀粉则有减轻脂质过氧化作用。这些抗氧化营养素缺乏时,机体抗氧化能力下降,多不饱和脂肪酸发生脂质过氧化而导致组织、细胞等损害。因此,在治疗这些营养缺乏病时,不仅要补给所缺乏的营养素,而且还要给予其他抗氧化剂,以协同作用,取得较好的治疗效果。     

MLT抑制E2诱发的大鼠垂体PRL瘤的增生涉及雌激素受体的作用

目的：探讨褪黑素（melatonin,MLT）抑制17-β-雌二醇（17-β-estradiol,E2）诱发垂体催乳素（prolactin,PRL）瘤的增生及其机制的初始阶段,MLT对雌激素受体的作用。方法：在体实验采用每日定时给各组SD大鼠分别皮下注射不同浓度的MLT,建立MLT抑制E2诱发的垂体PRL瘤增生的动物模型。离体实验采用原代培养细胞原位杂交方法,探讨垂体PRL瘤细胞MLT受体的表达、MLT对雌激素受体（ER）表达的作用;应用电泳迁移率改变（EMSA）的方法,观察MLT对雌激素受体（ER）与雌激素反应元件（ERE）结合的效应。结果：每只大鼠每日定时皮下注射0．25或0．50mg MLT能显著抑制E2诱发的垂体PRL瘤的增生（分别P〈0．01、P〈0．05）;F4诱发的垂体PRL瘤细胞内有MLT受体MLT1a和MLT1b;给0．25mg／day／rat MLT组的大鼠垂体PRL瘤细胞内ER的表达显著减少（P〈0．01）、ER与ERE的结合量显著降低（P〈0．01）。结论：一定剂量的MLT能显著抑制E2诱发的SD大鼠垂体PRL瘤的增生,其作用机制之一可能与MLT抑制ER的表达、及其部分阻断ER与ERE的结合有关。     

雌性大熊猫发情期尿中17β—雌二醇与孕酮水平的变化及其与配种的关系

本文用放射免疫法测定了3头雌性大熊猫(Ailuropoda melanoleuca)发情期尿中17β-雌二醇与孕酮水平的变化。大熊猫的发情行为与尿中17β-雌二醇浓度的变化密切相关。发情期中,随着孕酮水平下降的同时雌二醇水平却迅速上升并达峰值(28.2—65.5毫微克/毫克肌酐),然后再下降到基础水平。性活动最强烈的日期发生在17β-雌二醇最高峰值的当天或峰后一天。在雌二醇峰后,尿中孕酮水平逐步升高,发情后期的孕酮平均值显著高于发情前期(P<0.01)。本实验中,3头大熊猫均妊娠,说明自然交配或人工授精的适宜时间可根据雌性大熊猫尿中17β-雌二醇的监测予以确定。     

癌症中与脂质过氧化相关的铁死亡抑制机制

铁死亡(ferroptosis)是近年来发现的一种细胞死亡方式，以铁依赖和脂质过氧化(lipid peroxidation)为特点，有别于凋亡等其他细胞程序性死亡。诱导或促进细胞铁死亡也成为很有前景的肿瘤治疗方向。但在一些肿瘤中，癌细胞对铁死亡的敏感性下降，甚至顽固性抵抗死亡；除此之外，临床前实验中耐铁死亡诱导剂癌细胞的出现也引起隐忧。因此，明确肿瘤细胞抵抗铁死亡的机制，探索可能的靶向策略、削弱其对铁死亡的耐受程度，可以为肿瘤治疗提供帮助。铁死亡是在不同因素作用下，由活性氧产生、脂质过氧化、质膜受损和细胞死亡等系列事件组成的过程。其中，细胞质膜的脂质过氧化是铁死亡执行过程的核心阶段，对质膜的完整性、细胞存亡发挥决定性作用。本文将聚焦于这一关键事件，介绍其发生发展过程及其导致细胞死亡的可能机制，从膜磷脂组成、氧化级联反应、脂质过氧化物的清除和受损质膜的修复等方面，汇总近年来关于肿瘤细胞抑制脂质过氧化和抵抗铁死亡的研究进展，以及这些研究成果为提高肿瘤治疗效果提供的思路，为拓展铁死亡敏感性肿瘤的药物治疗、寻求铁死亡耐受肿瘤的药物治疗方案提供线索。     

4—PU和6—BA对萝卜离体子叶衰老的延缓和脂质过氧化的影响

自70年代在植物衰老研究中引入自由基假说后,国内外不少研究表明在叶片衰老过程中确有自由基的参与,并导致脂质过氧化。近年来,许多研究者在植物生长调节物质延缓或加速植物衰老作用机理的研究中也非常重视自由基的作用。Leopold和Kriedemann〔1〕指出激动素有“基于自身氧化的刹车作用”。Leshem等〔2〕和Dhindsa等〔3〕报告细胞分裂素在延缓植物衰老方面的作用与它能清除自由基、阻止自由基的形成有关。李伯林等〔4〕用燕麦叶片为材料,发现6BA和2,4D在植物体内可作为直接和间接的自由基清除剂而延缓植物的衰老。早在50年代中后期就有报…     

Role of 17-beta-estradiol in the synthesis and secretion of prolactin]

In 5 post-menopausal women TSH and prolactin secretions, induced by TRH, were studied before and after treatment with mg 20 of polyestradiol valerate. After this drug, plasma prolactin concentration increased, but no difference was observed in TSH secretion. The data suggest that 17-beta-estradiol doesn't increase the number of TRH receptors on pituitary cell surface, but stimulates prolactin synthesis.     

Sex-dependent effects of 17-beta-estradiol on chondrocyte differentiation in culture

This study examined the effects of 17-beta-estradiol (E₂) on chondrocyte differentiation in vitro. Cells derived from male or female rat costochondral growth zone and resting zone cartilage were used to determine whether the effects of E₂ were dependent on the stage of chondrocyte maturation and whether they were sex-specific. [³H]-incorporation, cell number, alkaline phosphatase specific activity, and percent collagen production were used as indicators of differentiation. Alakaline phosphatase specific activity in matrix vesicles and plasma membranes isolated from female chondrocyte cultures was measured to determine which membrane fraction was targeted by the hormone. Specificity of the E₂ effects was assessed using 17-alpha-estradiol. The role of fetal bovine serum and phenol red in the culture medium was also addressed. The results demonstrated that E₂ decreases cell number and [³H]-incorporation in female chondrocytes, indicating that it promotes differentiation of these cells. Alkaline phosphatase specific activity is stimulated in both growth zone and resting zone cells, but the effect is greater in the less mature resting zone chondrocytes. The increase in enzyme activity is targeted to the matrix vesicles in both cell types, but the fold increase is greater in the growth zone cells. In male chondrocytes, there was a decrease in [³H]-incorporation at high E₂ concentrations in resting zone cells at the earliest time point examined (12 hours) and a slight stimulation in alkaline phosphatase activity in growth zone cells at 24 hours. Cells cultured in serum-free medium exhibited a dose-dependent inhibition in alkaline phosphatase activity when cultured with E₂, even in the presence of phenol red. E₂-stimulation of enzyme activity is seen only in the presence of serum, suggesting that serum factors are also necessary. E₂ increased percent collagen production in female cells only; the magnitude of the effect was greatest in the resting zone chondrocyte cultures. The results of this study indicate that the effects of E₂ are dependent on time of exposure, presence of serum, and the sex and state of maturation of the chondrocytes. E₂-stimulation of alkaline phosphatase specific activity is targeted to matrix vesicles. © 1993 Wiley-Liss, Inc.     

Thermoregulatory effects of melatonin in relation to sleepiness

Thermoregulatory processes have long been implicated in the initiation of human sleep. In this paper, we review our own studies conducted over the last decade showing a crucial role for melatonin as a mediator between the thermoregulatory and arousal system in humans. Distal heat loss, via increased skin temperature, seems to be intimately coupled with increased sleepiness and sleep induction. Exogenous melatonin administration during the day when melatonin is essentially absent mimics the endogenous thermophysiological processes occurring in the evening and induces sleepiness. Using a cold thermic challenge test, it was shown that melatonin‐induced sleepiness occurs in parallel with reduction in the thermoregulatory set‐point (threshold); thus, melatonin may act as a circadian modulator of the thermoregulatory set‐point. In addition, an orthostatic challenge can partially block the melatonin‐induced effects, suggesting an important role of the sympathetic nervous system as a link between the thermoregulatory and arousal systems. A topographical analysis of finger skin temperature with infrared thermometry revealed that the most distal parts of the fingers, i.e., fingertips, represent the important skin regions for heat loss regulation, most probably via opening the arteriovenous anastomoses, and this is clearly potentiated by melatonin. Taken together, melatonin is involved in the fine‐tuning of vascular tone in selective vascular beds, as circulating melatonin levels rise and fall throughout the night. Besides the role of melatonin as “nature's soporific”, it can also serve as nature's nocturnal vascular modulator.     

Thermoregulatory effects of melatonin in relation to sleepiness

Thermoregulatory processes have long been implicated in the initiation of human sleep. In this paper, we review our own studies conducted over the last decade showing a crucial role for melatonin as a mediator between the thermoregulatory and arousal system in humans. Distal heat loss, via increased skin temperature, seems to be intimately coupled with increased sleepiness and sleep induction. Exogenous melatonin administration during the day when melatonin is essentially absent mimics the endogenous thermophysiological processes occurring in the evening and induces sleepiness. Using a cold thermic challenge test, it was shown that melatonin-induced sleepiness occurs in parallel with reduction in the thermoregulatory set-point (threshold); thus, melatonin may act as a circadian modulator of the thermoregulatory set-point. In addition, an orthostatic challenge can partially block the melatonin-induced effects, suggesting an important role of the sympathetic nervous system as a link between the thermoregulatory and arousal systems. A topographical analysis of finger skin temperature with infrared thermometry revealed that the most distal parts of the fingers, i.e., fingertips, represent the important skin regions for heat loss regulation, most probably via opening the arteriovenous anastomoses, and this is clearly potentiated by melatonin. Taken together, melatonin is involved in the fine-tuning of vascular tone in selective vascular beds, as circulating melatonin levels rise and fall throughout the night. Besides the role of melatonin as "nature's soporific", it can also serve as nature's nocturnal vascular modulator.     

Inhibitory effect of prolactin on the development of fatty liver induced by ACTH in thrat.

The action and interaction of ACTH and prolactin in the development of fatty liver were investigated in intact rats treated with exogenous hormones. Administration of ACTH or of combinations of ACTH and GH to intact female rats was found to elicit significantly greater increase in liver total lipids content and concentration than administration of combinations of ACTH, or ACTH and GH, with prolactin. In addition, the results support the data reported by Bates et al. (6) that simultaneous application of GH, prolactin and ACTH reduces the effct of ACTH, upon adrenal gland weight.     

Inhibitory effects of indomethacin on prolactin liberation induced with peptides with opium-like activity

Indomethacin inhibits prolactin liberating effects by MET-enkefalin-NH2, a synthetic analogue of MET-enkefalin, both in intact and in ovariectomized, estradiol benzoate treated rats. The introduction of PGE1 increases the intensity of this effect. It is therefore possible to suppose that the PGs are involved as intermediaries of the prolactin relasing effect induced by MET-ENH-NH2.     

Inhibitory effects of Celiptium on thymidine kinase synthesis induced in the uterus by 17 beta-estradiol

Inhibitory effects of Celiptium on the thymidine kinase synthesis induced by oestradiol-17 beta in the rat uterus. In the rat uterus, the synthesis of thymidine kinase specifically induced by oestradiol-17 beta was inhibited by Celiptium. The synthesis was totally inhibited when the drug was administered before the oestrogen and partially when it was administered after. These facts suggested that Celiptium was competitive to the acceptor sites for oestradiol-receptors and inhibited the expression of the thymidine kinase gene.     

Effects of shortened daylength and melatonin treatment on plasma prolactin and melatonin levels in pinealectomised and sham-operated ewes

Comparisons have been made between the effects of shortened daylength and melatonin treatment on plasma prolactin and melatonin levels in pinealectomised (Px) and sham-operated (Sh) ewes. Twenty-two anoestrous Merino crossbred ewes, maintained under normal grazing conditions, were assigned to four groups for a period of 9 weeks. Group 1 remained untreated (control), Group 2 was herded into a dark shed at 1600 h each day until dark (approx 4 h), ewes in Group 3 were injected with 100 μg melatonin s.c. at 1600 h each day and ewes in Group 4 were implanted with a melatonin capsule releasing 125–200 μg/day. Another group (Group 5) of 4 Px and 4 Sh ewes from the same flock was maintained in an animal house and subjected to shortened daylength (10. 5 h L : 13. 5 h D, lights off 1600 h). Three weeks after the treatments began, ewes in Groups 1–4 were exposed to a fertile ram and ewes in Group 5 to a vasectomised ram and the day of mating noted. No differences were evident between Groups 1–4 in the ewes' response to the ram, time taken to conceive, duration of gestation or number of lambs born. In untreated Px ewes no plasma melatonin (< 20 pg/ml) was found in either day or night samples, whereas intact animals showed the characteristic night-time rise. The silastic implants produced stable daytime blood levels of 90–120 pg/ml, whereas a single injection of 100 μg melatonin caused a transitory (2–3 h) rise. Shortened daylength (Group 2) or a single daily injection of melatonin (Group 3) lowered prolactin levels but only in ewes with an intact pineal gland, whereas melatonin implants (Group 4) caused a reduction in plasma prolactin in both Px and Sh sheep. The results indicate that light-induced alterations in prolactin production in sheep involve both the pineal gland and melatonin. Continuous melatonin release from implants caused changes in plasma prolactin levels similar to those seen following exposure to short days.